Shanghai Everest Medicines has started operations in its $130 million mRNA vaccine production facility, located in Jiashan, Zhejiang Province. In September 2021, Everest announced a $500 million two-part mRNA deal with Providence Therapeutics of Calvary, Canada. Initially, Everest acquired China-Asia rights to Providence’s mRNA Phase II COVID-19 vaccine and then began a 50/50 global collaboration for two additional Providence mRNA prophylactic or therapeutic products. Everest said it has completed industrial scale technology transfer of the mRNA platform along with other tasks that will allow…